Results 51 to 60 of about 898 (115)

Efficacy and Safety of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta‐Analysis

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life‐threatening disorder characterized by complement‐mediated hemolysis. Crovalimab, a novel anti‐C5 monoclonal antibody, may offer a more convenient alternative to current therapies, highlighting the need for a comprehensive analysis of its efficacy and safety.
Hammad Javaid, Maria Qadri, Hameer Ali, Chika Franklin Chilaka, Wajiha Syed, Erum Habib, Fahmida Zahin, Ayaan Musani, Salauddin Ali Khan, Daniah Rizwan, Muhammad Nabeel Saddique, Fatima Hajj   +11 more
wiley   +1 more source

The road ahead: emerging therapies for primary IgA nephropathy

Frontiers in Nephrology
Primary IgA nephropathy (IgAN) is the most common form of primary glomerulopathy. A slowly progressive disease presenting in the young to middle-aged, most patients with reduced eGFR or proteinuria will progress to end-stage kidney disease (ESKD) in ...
Edward J. Filippone, Rakesh Gulati, John L. Farber   +2 more
doaj   +1 more source

The treatment of autoimmune hemolytic anemia with complement inhibitor iptacopan: a case report

Frontiers in Medicine
Autoimmune hemolytic anemia (AIHA) is a type of hemolytic anemia. In this condition, the body produces anti-red blood cell autoantibodies due to immune dysfunction. This results in accelerated destruction of red blood cells.
Xiaoqing Li, Minran Zhou, Sai Ma, Ran Wang, Chuanli Zhao, Chunyan Chen   +5 more
doaj   +1 more source

Successful targeting of the alternative complement cascade with iptacopan for the treatment of IgA nephropathy: a case report

Swiss Medical Weekly
INTRODUCTION: Currently, approved disease-specific therapies for patients with immunoglobulin (Ig) A nephropathy in Switzerland are scarce. According to the 2024 KDIGO guidelines, current treatments focus on reducing proteinuria and nephron loss using ...
Leonore Ingold, Michael Dickenmann, Thomas Menter, Helmut Hopfer, Patricia Hirt-Minkowski   +4 more
doaj   +1 more source

Exploring Potential Complement Modulation Strategies for Ischemia–Reperfusion Injury in Kidney Transplantation

Antioxidants
The complement system plays a crucial role in regulating the inflammatory responses in kidney transplantation, potentially contributing to early decline in kidney function.
Dario Troise, Costanza Allegra, Luciana Antonia Cirolla, Silvia Mercuri, Barbara Infante, Giuseppe Castellano, Giovanni Stallone   +6 more
doaj   +1 more source

Primary membranoproliferative glomerulonephritis: natural history, pathogenesis, and treatment

Frontiers in Nephrology
Primary membranoproliferative glomerulonephritis (MPGN) is an ultrarare disease characterized by immunofluorescence microscopy as either immune-complex mediated (IC-MPGN) or C3 glomerulopathy (C3), the latter subdivided by electron microscopy to C3 ...
Edward J. Filippone, John L. Farber
doaj   +1 more source

Case report: persistent anemia after eculizumab in paroxysmal nocturnal hemoglobinuria: non-dominantly active intravascular hemolysis

Hematology
Objectives Paroxysmal nocturnal hemoglobinuria (PNH) is a rare condition characterized by intravascular hemolysis (IVH), thrombosis, and organ damage.
Baozhi Fang, Xiao Yu, Yifei Zhou, Qiudan Shen, Muzhi Yuan, Peng Wang, Mingen Lü, Guangsheng He   +7 more
doaj   +1 more source

Invited letter MUC4 mutations as an amplifier of complement‐mediated thrombosis in paroxysmal nocturnal haemoglobinuria

Clinical and Translational Discovery, Volume 6, Issue 2, April 2026.
Eng Soo Yap, Edwin Wei Sheng Thong, Cheryl Xiu Qi Lim   +2 more
wiley   +1 more source

Complement and transplant‐associated thrombotic microangiopathy: Current and future approaches

HemaSphere, Volume 10, Issue 4, April 2026.
Massimo Cugno, Francesco Onida, Bernhard Lämmle   +2 more
wiley   +1 more source

EFFICACY AND SAFETY OF IPTACOPAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Hematology, Transfusion and Cell Therapy
Objectives: Paroxysmal Nocturnal Hemoglobinuria (PNH) is a genetic disorder caused by a somatic mutation in the PIGA gene, which affects the functions of (GPI)-anchored proteins and impacts the regulation of complement activity.
VC Monici, IM Almeida, MEF Carvalho, MM Almeida, VN Binda, VC Destefani, AC Destefani, GJS Sanchez   +7 more
doaj   +1 more source